Stampacchia Otello
SEC-identified person · CIK 1361712 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Imagenebio, Inc. IMA | Director | filed 2021 - 2026 |
| Lexeo Therapeutics, Inc. LXEO | Officer | filed 2023 - 2023 |
| Kronos Bio, Inc. KRON | Director | filed 2020 - 2022 |
| Replimune Group, Inc. REPL | Director | filed 2018 - 2022 |
| Theseus Pharmaceuticals, Inc. THRX | Officer | filed 2021 - 2021 |
| Morphic Holding, Inc. MORF | Director | filed 2019 - 2021 |
| Panacea Acquisition Corp PANA | Officer | filed 2021 - 2021 |
| Omega Alpha Spac OMEG | Director · Chief Executive Officer | filed 2021 - 2021 |
| Gossamer Bio, Inc. GOSS | Director | filed 2019 - 2019 |
| Vital Therapies INC VTL | Officer | filed 2019 - 2019 |
| Translate Bio, Inc. TBIO | Officer | filed 2018 - 2018 |
| Kezar Life Sciences, Inc. KZR | Officer | filed 2018 - 2018 |
| Transcept Pharmaceuticals Inc TSPT | Officer | filed 2014 - 2014 |
| Micromet, INC. MITI | Director | filed 2006 - 2010 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.